| Year |
Citation |
Score |
| 2024 |
Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G. Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia. The International Journal of Neuropsychopharmacology. PMID 38195245 DOI: 10.1093/ijnp/pyae005 |
0.486 |
|
| 2023 |
Shamshoum H, Medak KD, McKie GL, Jeromson S, Hahn MK, Wright DC. Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 168: 115671. PMID 37839107 DOI: 10.1016/j.biopha.2023.115671 |
0.309 |
|
| 2023 |
Agarwal SM, Dissanayake J, Agid O, Bowie C, Brierley N, Chintoh A, De Luca V, Diaconescu A, Gerretsen P, Graff-Guerrero A, Hawco C, Herman Y, Hill S, Hum K, Husain MO, ... ... Hahn M, et al. Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol. Plos One. 18: e0288354. PMID 37733693 DOI: 10.1371/journal.pone.0288354 |
0.429 |
|
| 2023 |
Smith ECC, Au E, Pereira S, Sharma E, Venkatasubramanian G, Remington G, Agarwal SM, Hahn M. Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review. Psychiatry Research. 328: 115472. PMID 37722239 DOI: 10.1016/j.psychres.2023.115472 |
0.549 |
|
| 2023 |
Wu S, Stogios N, Hahn M, Navagnanavel J, Emami Z, Chintoh A, Gerretsen P, Graff-Guerrero A, Rajji TK, Remington G, Agarwal SM. Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis. Plos One. 18: e0286887. PMID 37379265 DOI: 10.1371/journal.pone.0286887 |
0.424 |
|
| 2023 |
Prasad F, Hahn MK, Chintoh AF, Remington G, Foussias G, Rotenberg M, Agarwal SM. Depression in caregivers of patients with schizophrenia: a scoping review. Social Psychiatry and Psychiatric Epidemiology. PMID 37308691 DOI: 10.1007/s00127-023-02504-1 |
0.456 |
|
| 2023 |
Lee J, Costa-Dookhan K, Panganiban K, MacKenzie N, Treen QC, Chintoh A, Remington G, Müller DJ, Sockalingam S, Gerretsen P, Sanches M, Karnovsky A, Stringer KA, Ellingrod VL, Tso IF, ... ... Hahn MK, et al. Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study. Frontiers in Psychiatry. 14: 1169787. PMID 37168086 DOI: 10.3389/fpsyt.2023.1169787 |
0.451 |
|
| 2023 |
Prasad F, De R, Korann V, Chintoh AF, Remington G, Ebdrup BH, Siskind D, Knop FK, Vilsbøll T, Fink-Jensen A, Hahn MK, Agarwal SM. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Therapeutic Advances in Psychopharmacology. 13: 20451253231165169. PMID 37113745 DOI: 10.1177/20451253231165169 |
0.42 |
|
| 2023 |
Agarwal SM, Stogios N, Faulkner GEJ, Hahn M. Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis. Schizophrenia Bulletin. PMID 37002951 DOI: 10.1093/schbul/sbad037 |
0.348 |
|
| 2023 |
Medak KD, Weber AJ, Shamshoum H, McKie GL, Hahn MK, Wright DC. Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism. Frontiers in Pharmacology. 14: 1127634. PMID 36937886 DOI: 10.3389/fphar.2023.1127634 |
0.31 |
|
| 2023 |
Pereira S, Au E, Agarwal SM, Wright DC, Hahn MK. Antipsychotic-induced alterations in lipid turnover. Endocrinology. PMID 36718081 DOI: 10.1210/endocr/bqad025 |
0.312 |
|
| 2022 |
Stogios N, Hamel L, Smith E, Sanches M, Remington G, Voineskos A, Dash S, Graff-Guerrero A, Hahn M, Agarwal SM. Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls. Plos One. 17: e0277211. PMID 36441736 DOI: 10.1371/journal.pone.0277211 |
0.476 |
|
| 2022 |
Castellani LN, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S, Hamel L, Alganem K, Ryan WG, Zhang X, Au E, Chintoh A, Remington G, Agarwal SM, Giacca A, ... ... Hahn MK, et al. Antipsychotics impair regulation of glucose metabolism by central glucose. Molecular Psychiatry. PMID 36241692 DOI: 10.1038/s41380-022-01798-y |
0.48 |
|
| 2022 |
Agarwal SM, Stogios N, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia. The Cochrane Database of Systematic Reviews. 10: CD013337. PMID 36190739 DOI: 10.1002/14651858.CD013337.pub2 |
0.498 |
|
| 2022 |
Smith E, Stogios N, Au E, Maksyutynska K, De R, Ji A, Sørensen ME, John LS, Lin HY, Desarkar P, Lunsky Y, Remington G, Hahn M, Agarwal SM. The Metabolic Adverse Effects of Antipsychotic Use in Individuals with Intellectual and/or Developmental Disability (IDD): A Systematic Review and Meta-Analysis. Acta Psychiatrica Scandinavica. PMID 35894550 DOI: 10.1111/acps.13484 |
0.462 |
|
| 2022 |
Stogios N, Maksyutynska K, Navagnanavel J, Sanches M, Powell V, Gerretsen P, Graff-Guerrero A, Chintoh AF, Foussias G, Remington G, Hahn MK, Agarwal SM. Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica. PMID 35726126 DOI: 10.1111/acps.13462 |
0.518 |
|
| 2022 |
Singh R, Stogios N, Smith E, Lee J, Maksyutynsk K, Au E, Wright DC, De Palma G, Graff-Guerrero A, Gerretsen P, Müller DJ, Remington G, Hahn M, Agarwal SM. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Therapeutic Advances in Psychopharmacology. 12: 20451253221096525. PMID 35600753 DOI: 10.1177/20451253221096525 |
0.503 |
|
| 2022 |
Henkel ND, Wu X, O'Donovan SM, Devine EA, Jiron JM, Rowland LM, Sarnyai Z, Ramsey AJ, Wen Z, Hahn MK, McCullumsmith RE. Schizophrenia: a disorder of broken brain bioenergetics. Molecular Psychiatry. PMID 35264726 DOI: 10.1038/s41380-022-01494-x |
0.342 |
|
| 2021 |
Smith E, Singh R, Lee J, Colucci L, Graff-Guerrero A, Remington G, Hahn M, Agarwal SM. Adiposity in Schizophrenia: A Systematic Review and Meta-Analysis. Acta Psychiatrica Scandinavica. PMID 34458979 DOI: 10.1111/acps.13365 |
0.525 |
|
| 2021 |
Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34446830 DOI: 10.1038/s41386-021-01163-7 |
0.467 |
|
| 2021 |
Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: Antipsychotics and Drug Development. Behavioural Brain Research. 113507. PMID 34352293 DOI: 10.1016/j.bbr.2021.113507 |
0.486 |
|
| 2021 |
Stogios N, Gdanski A, Gerretsen P, Chintoh AF, Graff-Guerrero A, Rajji TK, Remington G, Hahn MK, Agarwal SM. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. Npj Schizophrenia. 7: 22. PMID 33903594 DOI: 10.1038/s41537-021-00151-6 |
0.505 |
|
| 2021 |
Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani A, Matheson K, Chintoh AF, Kramer CK, Voineskos AN, Graff-Guerrero A, Remington GJ, ... Hahn MK, et al. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Translational Psychiatry. 11: 219. PMID 33854039 DOI: 10.1038/s41398-021-01338-2 |
0.531 |
|
| 2021 |
Kanagasundaram P, Lee J, Prasad F, Costa-Dookhan KA, Hamel L, Gordon M, Remington G, Hahn MK, Agarwal SM. Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. Frontiers in Psychiatry. 12: 642403. PMID 33815174 DOI: 10.3389/fpsyt.2021.642403 |
0.448 |
|
| 2021 |
Liu JCW, Gorbovskaya I, Hahn MK, Müller DJ. The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. Nutrients. 13. PMID 33807241 DOI: 10.3390/nu13041152 |
0.355 |
|
| 2021 |
Costa-Dookhan KA, Rajji TK, Tran VN, Bowden S, Mueller DJ, Remington GJ, Agarwal SM, Hahn MK. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Scientific Reports. 11: 2004. PMID 33479273 DOI: 10.1038/s41598-021-81493-0 |
0.526 |
|
| 2021 |
Prestwood TR, Asgariroozbehani R, Wu S, Agarwal SM, Logan RW, Ballon JS, Hahn MK, Freyberg Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behavioural Brain Research. 113101. PMID 33453341 DOI: 10.1016/j.bbr.2020.113101 |
0.375 |
|
| 2020 |
Hahn MK, Panda R. Mortality Risk Following Acute Coronary Syndrome Among Patients With Schizophrenia Spectrum Disorders-Addressing the Gaps. Schizophrenia Bulletin. PMID 32390053 DOI: 10.1093/Schbul/Sbaa064 |
0.352 |
|
| 2020 |
Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research. 124: 151-158. PMID 32169688 DOI: 10.1016/J.Jpsychires.2020.02.032 |
0.542 |
|
| 2020 |
Agarwal SM, Stogios N, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE Schizophrenia Bulletin. 46: S68-S68. DOI: 10.1093/Schbul/Sbaa031.156 |
0.413 |
|
| 2020 |
Costa-Dookhan K, Mahavir Agarwal S, Chintoh A, Mackenzie N, Casuccio-Treen Q, Remington G, Ward K, Hahn M. S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS Schizophrenia Bulletin. 46: S68-S68. DOI: 10.1093/Schbul/Sbaa031.155 |
0.388 |
|
| 2020 |
Agarwal SM, Panda R, Costa-Dookhan K, Mackenzie N, Casuccio-Treen Q, Caravaggio F, Eyesha H, Kirpalani A, Chintoh A, Voineskos A, Kramer C, Graff-Guerrero A, Remington G, Hahn M. M84. Metformin For Early Co-Morbid Prediabetes Or Diabetes In Schizophrenia Spectrum Disorders: A Double Blind Randomized Pilot Study Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa030.396 |
0.372 |
|
| 2020 |
Chintoh A, Agarwal M, Mackenzie N, Remington G, Hahn M. T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS Schizophrenia Bulletin. 46: S321-S321. DOI: 10.1093/Schbul/Sbaa029.791 |
0.375 |
|
| 2020 |
Bowden S, Tran V, Asgariroozbehani R, Brett McIntyre W, Agarwal M, Siskind D, Hahn M. T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS Schizophrenia Bulletin. 46: S311-S311. DOI: 10.1093/Schbul/Sbaa029.767 |
0.389 |
|
| 2020 |
Castellani L, Kowalchuk C, Asgariroozbehani R, Tran V, Brett McIntyre W, Hamel L, Remington G, Giacca A, Hahn M. O9.2. ANTIPSYCHOTIC DRUGS IMPAIR BRAIN GLUCOSE SENSING RESULTING IN WHOLE BODY INSULIN RESISTANCE Schizophrenia Bulletin. 46: S21-S21. DOI: 10.1093/Schbul/Sbaa028.049 |
0.399 |
|
| 2020 |
Stogios N, Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.915 |
0.554 |
|
| 2020 |
Hahn M, Agarwal SM, Costa-Dookhan K, Roshni P, Nicole M, Cauccio-Treen Q, Caravaggio F, Hashim E, Kirpalani A, Chintoh A, Kramer C, Voineskos A, Graff-Guerrero A, Remington G. Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1057 |
0.525 |
|
| 2020 |
Costa-Dookhan K, Agarwal SM, Chintoh A, MacKenzie N, Leavitt D, Treen QC, Remington G, Ward K, Hahn M. Investigating Metabolic Dysfunction and Metabolomic Profile Changes in Antipsychotic Naive Patients Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1041 |
0.501 |
|
| 2019 |
Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion On Drug Safety. PMID 31770500 DOI: 10.1080/14740338.2020.1698545 |
0.556 |
|
| 2019 |
Shamshoum H, Medak KD, Townsend LK, Ashworth KE, Bush ND, Hahn MK, Kemp BE, Wright DC. AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201901820R. PMID 31581839 DOI: 10.1096/Fj.201901820R |
0.314 |
|
| 2019 |
Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opinion On Drug Safety. PMID 31564170 DOI: 10.1080/14740338.2019.1674809 |
0.461 |
|
| 2019 |
Medak KD, Townsend LK, Hahn MK, Wright DC. Female mice are protected against acute olanzapine-induced hyperglycemia. Psychoneuroendocrinology. 110: 104413. PMID 31499390 DOI: 10.1016/J.Psyneuen.2019.104413 |
0.36 |
|
| 2019 |
Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience. PMID 31428862 DOI: 10.1007/S00406-019-01053-6 |
0.537 |
|
| 2019 |
Kowalchuk C, Kanagasundaram P, McIntyre WB, Belsham DD, Hahn MK. Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons. Psychoneuroendocrinology. 109: 104400. PMID 31404896 DOI: 10.1016/J.Psyneuen.2019.104400 |
0.355 |
|
| 2019 |
Agarwal SM, Kowalchuk C, Castellani L, Costa-Dookhan KA, Caravaggio F, Asgariroozbehani R, Chintoh A, Graff-Guerrero A, Hahn M. Brain insulin action: implications for the treatment of schizophrenia. Neuropharmacology. PMID 31152767 DOI: 10.1016/J.Neuropharm.2019.05.032 |
0.48 |
|
| 2019 |
Agarwal SM, Caravaggio F, Costa-Dookhan KA, Castellani L, Kowalchuk C, Asgariroozbehani R, Graff-Guerrero A, Hahn M. Brain insulin action in schizophrenia: something borrowed and something new. Neuropharmacology. PMID 31077731 DOI: 10.1016/J.Neuropharm.2019.05.010 |
0.453 |
|
| 2019 |
Gorbovskaya I, Kanji S, Liu JCW, MacKenzie NE, Agarwal SM, Marshe VS, Sriretnakumar V, Verdu EF, Bercik P, De Palma G, Hahn MK, Müller DJ. Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. Neuropsychobiology. 1-8. PMID 30928978 DOI: 10.1159/000494696 |
0.388 |
|
| 2019 |
Kowalchuk C, Kanagasundaram P, Belsham DD, Hahn MK. Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. Psychoneuroendocrinology. 104: 42-48. PMID 30802709 DOI: 10.1016/J.Psyneuen.2019.01.029 |
0.394 |
|
| 2019 |
Shah P, Iwata Y, Caravaggio F, Plitman E, Brown EE, Kim J, Chan N, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research. PMID 30685395 DOI: 10.1016/j.schres.2019.01.005 |
0.47 |
|
| 2019 |
Shah P, Iwata Y, Brown E, Caravaggio F, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.936 |
0.541 |
|
| 2019 |
Kowalchuk C, Castellani L, Teo C, Kanagasundaram P, McIntyre WB, Remington G, Giacca A, Hahn M. 52. Antipsychotics Perturb Glucose Homeostasis by Inhibiting Hypothalamic KATP Channel Activation Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.066 |
0.475 |
|
| 2019 |
Agarwal SM, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia Cochrane Database of Systematic Reviews. 2019. DOI: 10.1002/14651858.Cd013337 |
0.552 |
|
| 2018 |
MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry. 9: 622. PMID 30568606 DOI: 10.3389/Fpsyt.2018.00622 |
0.564 |
|
| 2018 |
Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor-agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes, Obesity & Metabolism. PMID 30187620 DOI: 10.1111/Dom.13522 |
0.443 |
|
| 2018 |
Castellani LN, Wilkin J, Abela A, Benarroch L, Ahasan Z, Teo C, Wilson V, Kowalchuk C, Giacca A, Remington GJ, Hahn MK. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 98: 127-130. PMID 30142549 DOI: 10.1016/J.Psyneuen.2018.07.028 |
0.502 |
|
| 2018 |
Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Research. 268: 114-122. PMID 30015109 DOI: 10.1016/j.psychres.2018.06.070 |
0.486 |
|
| 2018 |
Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. American Journal of Physiology. Endocrinology and Metabolism. PMID 29969315 DOI: 10.1152/Ajpendo.00164.2018 |
0.601 |
|
| 2018 |
Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA Schizophrenia Bulletin. 44: S413-S413. DOI: 10.1093/schbul/sby018.1012 |
0.491 |
|
| 2018 |
Kanji S, Gorbovskaya I, Fonseka T, Yoshida K, Marshe V, MacKenzie M, Bercik P, Verdu E, Hahn M, Mueller D. T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION Schizophrenia Bulletin. 44: S190-S191. DOI: 10.1093/Schbul/Sby016.468 |
0.432 |
|
| 2018 |
Castellani L, Wilkin J, Ahsan Z, Teo C, Kowalchuk C, Giacca A, Remington G, Hahn M. O10.6. OLANZAPINE IMPAIRS CENTRAL INSULIN ACTION: EFFECTS ON BODY FUEL PREFERENCE IN RATS Schizophrenia Bulletin. 44: S104-S105. DOI: 10.1093/Schbul/Sby015.258 |
0.47 |
|
| 2018 |
Chintoh A, MacKenzie N, Agarwal SM, Remington G, Hahn M. 2.21 Improvement and Stability of Quality of Life and Clinical Presentation in Youth Who Are First-Episode, Antipsychotic Naïve, and Experience Adverse Metabolic Side Effects Journal of the American Academy of Child & Adolescent Psychiatry. 57: S165. DOI: 10.1016/J.Jaac.2018.09.109 |
0.463 |
|
| 2018 |
Kowalchuk C, Kanagasundaram P, Remington G, Belsham D, Hahn M. T256. Differential Effects of Antipsychotics on Neuroinflammation and Energy Sensing in a Hypothalamic Cell Line Biological Psychiatry. 83: S228-S229. DOI: 10.1016/J.Biopsych.2018.02.593 |
0.428 |
|
| 2018 |
Castellani L, Wilkin J, Ahsan Z, Kowalchuk C, Teo C, Giacca A, Wright D, Remington G, Hahn M. 259. Olanzapine Impairs Central Insulin Action: Effects on Body Fuel Preference Biological Psychiatry. 83: S105. DOI: 10.1016/J.Biopsych.2018.02.278 |
0.488 |
|
| 2018 |
Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. S245. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction or Prevention of Weight Gain in Schizophrenia Biological Psychiatry. 83: S443. DOI: 10.1016/J.Biopsych.2018.02.1137 |
0.549 |
|
| 2017 |
Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Frontiers in Neuroscience. 11: 741. PMID 29403343 DOI: 10.3389/Fnins.2017.00741 |
0.46 |
|
| 2017 |
Caravaggio F, Iwata Y, Plitman E, Chavez S, Borlido C, Chung JK, Kim J, Agarwal SM, Gerretsen P, Remington G, Hahn M, Graff-Guerrero A. Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29269206 DOI: 10.1016/J.Euroneuro.2017.12.002 |
0.474 |
|
| 2017 |
Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 424-431. PMID 29083297 DOI: 10.1503/jpn.170092 |
0.527 |
|
| 2017 |
Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 170092. PMID 29035174 DOI: 10.1503/Jpn.170092 |
0.581 |
|
| 2017 |
Ragguett RM, Hahn M, Messina G, Chieffi S, Monda M, De Luca V. Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. Human Psychopharmacology. PMID 28980344 DOI: 10.1002/Hup.2631 |
0.427 |
|
| 2017 |
Kanji S, Fonseka TM, Marshe VS, Sriretnakumar V, Hahn MK, Müller DJ. The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. European Archives of Psychiatry and Clinical Neuroscience. PMID 28624847 DOI: 10.1007/S00406-017-0820-Z |
0.414 |
|
| 2017 |
Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Intervention in Psychiatry. PMID 28230315 DOI: 10.1111/Eip.12405 |
0.56 |
|
| 2017 |
Kowalchuk C, Teo C, Wilson V, Giacca A, Remington G, Hahn M. 61. Olanzapine Inhibits Central Insulin Action Resulting in Glucose Dysregulation Biological Psychiatry. 81: S25-S26. DOI: 10.1016/J.Biopsych.2017.02.072 |
0.336 |
|
| 2016 |
Amato D, Beasley CL, Hahn MK, Vernon AC. Neuroadaptations to antipsychotic drugs: insights from pre-clinical and human post-mortem studies. Neuroscience and Biobehavioral Reviews. PMID 27756689 DOI: 10.1016/J.Neubiorev.2016.10.004 |
0.419 |
|
| 2016 |
Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating Negative Symptoms in Schizophrenia: an Update. Current Treatment Options in Psychiatry. 3: 133-150. PMID 27376016 DOI: 10.1007/S40501-016-0075-8 |
0.534 |
|
| 2016 |
Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. PMID 27251130 DOI: 10.1007/S00213-016-4324-8 |
0.537 |
|
| 2016 |
Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V. Clozapine's Critical Role in Treatment Resistant Schizophrenia: Ensuring Both Safety and Use. Expert Opinion On Drug Safety. PMID 27207070 DOI: 10.1080/14740338.2016.1191468 |
0.543 |
|
| 2015 |
Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A, Hahn MK. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. The Journal of Endocrinology. 227: 71-81. PMID 26330531 DOI: 10.1530/Joe-15-0074 |
0.53 |
|
| 2015 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses. PMID 26118462 DOI: 10.1016/J.Mehy.2015.06.011 |
0.57 |
|
| 2015 |
Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: S14-8. PMID 25886675 |
0.511 |
|
| 2015 |
Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18: pyv014. PMID 25716779 DOI: 10.1093/Ijnp/Pyv014 |
0.48 |
|
| 2015 |
Hahn MK, Gomes S, Remington GJ. Low-Dose, Off-Label Quetiapine Use, Metabolic Syndrome and Impaired Fasting Glucose in an Elderly Man: A Case Report Brain Disorders & Therapy. 4: 1-2. DOI: 10.4172/2168-975X.1000149 |
0.356 |
|
| 2015 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia Medical Hypotheses. DOI: 10.1016/j.mehy.2015.06.011 |
0.47 |
|
| 2014 |
Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging. 31: 159-84. PMID 24477569 DOI: 10.1007/S40266-014-0152-X |
0.527 |
|
| 2014 |
Remington G, Hahn M. Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. Journal of Psychiatry & Neuroscience : Jpn. 39: E1-2. PMID 24359929 DOI: 10.1503/Jpn.130222 |
0.461 |
|
| 2014 |
Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophrenia Research. 152: 381-90. PMID 24206930 DOI: 10.1016/J.Schres.2013.10.009 |
0.551 |
|
| 2014 |
Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 448-58. PMID 24001874 DOI: 10.1016/J.Euroneuro.2013.07.011 |
0.534 |
|
| 2014 |
Hahn MK, Remington G, Chintoh A, Teo C, Fletcher P, Norbrega J, Guenette M, Cohn T, Giacca A. CLINCIAL INSIGHTS DERIVED FROM RODENT MODELS OF ANTIPSYCHOTIC-INDUCED METABOLIC PERTRUBATIONS Schizophrenia Research. 153: S70. DOI: 10.1016/S0920-9964(14)70226-9 |
0.496 |
|
| 2014 |
Hahn M, Remington G, Duncan MJ, Cohn T, Faulkner GEJ. Pharmacological interventions for reducing weight gain in schizophrenia Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd011127 |
0.42 |
|
| 2013 |
Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of Clinical Psychopharmacology. 33: 740-6. PMID 24100786 DOI: 10.1097/Jcp.0B013E31829E8333 |
0.494 |
|
| 2013 |
Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, Takeuchi H, Remington G. Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research. 148: 183-5. PMID 23727216 DOI: 10.1016/J.Schres.2013.05.001 |
0.419 |
|
| 2013 |
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, Arenovich T, Remington G. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophrenia Research. 146: 162-9. PMID 23499243 DOI: 10.1016/J.Schres.2013.02.023 |
0.523 |
|
| 2013 |
Remington G, Teo C, Mann S, Hahn M, Foussias G, Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. Journal of Clinical Psychopharmacology. 33: 261-3. PMID 23422390 DOI: 10.1097/Jcp.0B013E31828568Bc |
0.48 |
|
| 2013 |
Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine's role in the treatment of first-episode schizophrenia. The American Journal of Psychiatry. 170: 146-51. PMID 23377634 DOI: 10.1176/Appi.Ajp.2012.12060778 |
0.548 |
|
| 2013 |
Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 226: 1-12. PMID 23344556 DOI: 10.1007/S00213-013-2982-3 |
0.467 |
|
| 2013 |
Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clinical Schizophrenia & Related Psychoses. 6: 186-96. PMID 23302448 DOI: 10.3371/Csrp.Haco.01062013 |
0.615 |
|
| 2013 |
Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. Journal of Clinical Psychopharmacology. 33: 11-7. PMID 23277265 DOI: 10.1097/Jcp.0B013E31827D145A |
0.331 |
|
| 2013 |
Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacology, Biochemistry, and Behavior. 103: 717-22. PMID 23234835 DOI: 10.1016/J.Pbb.2012.12.002 |
0.495 |
|
| 2013 |
Faulkner G, Duncan MJ, Hahn M, Remington G, Cohn T. Behavioural interventions for reducing weight gain in schizophrenia Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd010781 |
0.415 |
|
| 2012 |
Hahn MK, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Poster #223 SINGLE DOSE ADMINISTRATION OF OLANZAPINE: EFFECTS ON GLUCOSE METABOLISM, ENDOCRINE AND INFLAMMATORY MARKERS IN HEALTHY VOLUNTEERS Schizophrenia Research. 136: S266. DOI: 10.1016/S0920-9964(12)70794-6 |
0.495 |
|
| 2012 |
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Poster #13 RECEPTOR BINDING PROFILES OF ANTIPSYCHOTIC MEDICATIONS AND GLUCOSE DYSREGULATION: AN ACUTE ANIMAL MODEL Schizophrenia Research. 136: S189. DOI: 10.1016/S0920-9964(12)70585-6 |
0.484 |
|
| 2012 |
Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, Remington G. Poster #195 EXAMINING LEVELS OF ANTIPSYCHOTIC ADHERENCE TO BETTER UNDERSTAND NONADHERENCE IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 136: S161. DOI: 10.1016/S0920-9964(12)70509-1 |
0.56 |
|
| 2011 |
Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacology, Biochemistry, and Behavior. 100: 86-9. PMID 21839766 DOI: 10.1016/J.Pbb.2011.07.019 |
0.448 |
|
| 2011 |
Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, Fletcher P, Guenette M, Cohn T, Wolever T, Arenovich T, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophrenia Research. 131: 90-5. PMID 21696923 DOI: 10.1097/01.Yic.0000405882.94837.86 |
0.529 |
|
| 2011 |
Hahn M, Chintoh A, Remington G, Fletcher P, Cohn T, Lam L, Mann S, Teo C, Giacca A. P.3.c.008 Intracerebroventricular olanzapine acutely suppresses b-cell secretion in vivo: an animal model European Neuropsychopharmacology. 21: S472. DOI: 10.1016/S0924-977X(11)70765-9 |
0.41 |
|
| 2010 |
Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 30: 706-10. PMID 21105286 DOI: 10.1097/Jcp.0B013E3181Fab67D |
0.596 |
|
| 2010 |
Hahn MK, Cohn T, Remington G. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. The Annals of Pharmacotherapy. 44: 1349-50; author repl. PMID 20587740 DOI: 10.1345/aph.1M550a |
0.437 |
|
| 2010 |
Hahn M, Chintoh A, Lam L, Mann S, Giacca A, Fletcher P, Remington G. P.3.f.007 Atypical antipsychotics and effects of muscarinic and serotonergic receptor binding on insulin secretion in a rat model European Neuropsychopharmacology. 20: S517. DOI: 10.1016/S0924-977X(10)70772-0 |
0.473 |
|
| Show low-probability matches. |